Infant Bacterial Therapeutics Delays Ph III Start Date After Meeting with FDA

Following its meeting with the US Food and Drug Administration (FDA) in Washington DC to discuss the design of the company’s clinical development program, IBT has chosen to modify its Phase III study of IBP-9414 for the prevention of necrotizing enterocolitis (NEC) in premature infants.